1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,050 | 1,075 | 12:41 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.12. | Aelis Farma Obtains Regulatory Approval of the Phase 2B Trial With AEF0217 in People With Down Syndrome | 289 | Business Wire | AEF0217 is a first-in-class CB1 receptor Signalling Specific inhibitor (CB1-SSi) developed as a potential first pharmacological treatment for impairments in adaptive behaviours and cognition... ► Artikel lesen | |
| 25.09. | Aelis Farma: Availability of the 2025 Half-Year Financial Report | 284 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| AELIS FARMA Aktie jetzt für 0€ handeln | |||||
| 22.09. | Aelis Farma Reports 2025 Half-Year Financial Results and Presents Progress and Development Outlook | 453 | Business Wire | The first half of 2025 was marked by: The publication of the final analysis of the pioneering Phase 2b clinical trial in cannabis use disorders (CUD) with the CB1-SSi AEF0117, which further... ► Artikel lesen | |
| 24.06. | Aelis Farma: Availability of the Description of the Share Buyback Program | 366 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 27.05. | Results of Aelis Farma Combined General Meeting of May 27, 2025 | 396 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 06.05. | Aelis Farma: Combined General Meeting of May 27, 2025: Availability of Preparatory Documents and Participation and Voting Procedures | 393 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 29.04. | Aelis Farma: Availability of the 2024 Universal Registration Document | 314 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 01.04. | Aelis Farma Reports Its 2024 Annual Financial Results and Confirms Its 2025 Outlook | 487 | Business Wire | 2024 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates:
AEF0117: announcement of the results of the Phase 2b clinical... ► Artikel lesen | |
| 26.03. | Aelis Farma Announces the Final Analysis of the Landmark Phase 2B Clinical Trial in Cannabis Use Disorder (CUD) with the CB1-SSi AEF0117 | 522 | Business Wire | The purpose of this pioneering Phase 2B trial was to show that AEF0117 reduces cannabis use and to determine the endpoints and optimal dosage to be used in future studies. AEF0117 is the first... ► Artikel lesen | |
| 17.02. | Aelis Farma Announces Its 2025 Financial Calendar | 346 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NURIX THERAPEUTICS | 18,520 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | -11,50 % | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | ||
| DYNE THERAPEUTICS | 19,850 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | +0,73 % | Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock | ||
| SUMMIT THERAPEUTICS | 17,820 | 0,00 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| RELAY THERAPEUTICS | 8,400 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| IMMUNEERING | 5,650 | 0,00 % | Immuneering Corporation: Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA | - End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA - - Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 -... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,010 | 0,00 % | Potenzial von Hustenmedikament: Stifel erhöht Kursziel für Trevi Therapeutics auf 18 Dollar | ||
| VIR BIOTECHNOLOGY | 5,760 | 0,00 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,32 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ABSCI | 3,380 | -0,88 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,580 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| VOR BIOPHARMA | 12,410 | 0,00 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| ARVINAS | 11,680 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen |
AELIS FARMA SAS gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,48 % bei einem Aktienkurs von 1,045 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AELIS FARMA SAS finden Sie auf Wallstreet Online.